David Henley

2.1k total citations
37 papers, 1.0k citations indexed

About

David Henley is a scholar working on Psychiatry and Mental health, Physiology and Economics and Econometrics. According to data from OpenAlex, David Henley has authored 37 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Psychiatry and Mental health, 15 papers in Physiology and 9 papers in Economics and Econometrics. Recurrent topics in David Henley's work include Dementia and Cognitive Impairment Research (22 papers), Alzheimer's disease research and treatments (14 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). David Henley is often cited by papers focused on Dementia and Cognitive Impairment Research (22 papers), Alzheimer's disease research and treatments (14 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). David Henley collaborates with scholars based in United States, New Zealand and Italy. David Henley's co-authors include Eric Siemers, Patrick C. May, Michael Case, Robert A. Dean, Olawale Osuntokun, Karen Sundell, Susan B. Watson, S. Corya, Michael E. Thase and Gopalan Sethuraman and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Neurology and Global Change Biology.

In The Last Decade

David Henley

37 papers receiving 969 citations

Peers

Countries citing papers authored by David Henley

Since Specialization

Citations

This map shows the geographic impact of David Henley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Henley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Henley more than expected).

Fields of papers citing papers by David Henley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Henley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Henley. The network helps show where David Henley may publish in the future.

Co-authorship network of co-authors of David Henley

This figure shows the co-authorship network connecting the top 25 collaborators of David Henley. A scholar is included among the top collaborators of David Henley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Henley. David Henley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial 2024 ·Neurology Clinical Practice ·Joshua D. Grill, Rema Raman, Karin Ernström, (unknown), Michael Donohue, Paul Aisen, Jason Karlawish, David Henley, Gary Romano, Gerald Novak, H. Robert Brashear, Reisa A. Sperling	5
2	Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease 2024 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Linda J. Van Eldik, Eric Siemers, Emily C. Collins, M. Gold, David Henley, Peter Johannsen, Hans Jörg Möbius, Melanie Shulman, (unknown), Marı́a C. Carrillo, Christopher J. Weber	1
3	The age-specific comorbidity burden of mild cognitive impairment: a US claims database study 2023 ·Alzheimer s Research & Therapy ·Gang Li, Nicola Toschi, Viswanath Devanarayan, Richard Batrla, (unknown), Min Cho, (unknown), Feride Frech, James E. Galvin, David Henley, Soeren Mattke, Susan De Santi, Harald Hampel	11
4	Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial 2022 ·The Journal of Prevention of Alzheimer s Disease ·Kathryn V. Papp, Hany Rofael, Amy E. Veroff, Michael Donohue, (unknown), Christopher Randolph, Ellen Grober, H. Robert Brashear, Gerald Novak, Karin Ernström, Rema Raman, Paul Aisen, Reisa A. Sperling, Gary Romano, David Henley	17
5	Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study 2020 ·Alzheimer s Research & Therapy ·Gerald Novak, Johannes Streffer, Maarten Timmers, David Henley, H. Robert Brashear, Jennifer Bogert, Alberto Russu, Luc Janssens, Ina Tesseur, Luc Tritsmans, Luc Van Nueten, Sebastiaan Engelborghs	73
6	Representativeness of European clinical trial populations in mild Alzheimer’s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study 2018 ·Alzheimer s Research & Therapy ·Catherine Reed, Mark Belger, Grazia Dell’Agnello, Kristin Kahle‐Wrobleski, Gopalan Sethuraman, Ann Marie Hake, Joel Raskin, David Henley	3
7	Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia 2016 ·IUScholarWorks (Indiana University) ·Elisabeth K. Degenhardt, Michael M. Witte, Michael Case, Peng Yu, David Henley, Helen Hochstetler, Deborah N. D’Souza, Paula T. Trzepacz	2
8	LONGITUDINAL TRAJECTORIES OF CLINICAL DECLINE IN AMYLOID POSITIVE AND NEGATIVE POPULATIONS 2016 ·The Journal of Prevention of Alzheimer s Disease ·Paula T. Trzepacz, Helen Hochstetler, (unknown), (unknown), M. Case, David Henley, Elisabeth K. Degenhardt, Jeannie‐Marie Leoutsakos, C.G. Lyketsos	3
9	Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline 2016 ·Journal of Alzheimer s Disease ·Helen Hochstetler, (unknown), Paula T. Trzepacz, Shufang Wang, Peng Yu, Michael Case, David Henley, Elisabeth K. Degenhardt, Jeannie‐Marie Leoutsakos, Constantine G. Lyketsos	14
10	Assessing quality of life in Alzheimer's disease: Implications for clinical trials 2016 ·Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring ·Kristin Kahle‐Wrobleski, Wenyu Ye, David Henley, Ann Marie Hake, Eric Siemers, (unknown), Hong Liu‐Seifert	43
11	Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline 2015 ·Publisher ·Helen Hochstetler, Paula T. Trzepacz, Shufang Wang, (unknown), Michael Case, David Henley, Elisabeth K. Degenhardt, Jeannie‐Marie Leoutsakos, Constantine G. Lyketsos	1
12	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease 2015 ·Journal of Alzheimer s Disease ·Hong Liu‐Seifert, (unknown), Eric Siemers, Karen Price, Baoguang Han, Katherine J. Selzler, David Henley, Karen Sundell, Paul Aisen, Jeffrey L. Cummings, Joel Raskin, Richard C. Mohs	62
13	Alzheimer’s disease progression by geographical region in a clinical trial setting 2015 ·Alzheimer s Research & Therapy ·David Henley, Sherie A. Dowsett, Yunfei Chen, Hong Liu‐Seifert, Joshua D. Grill, Rachelle S. Doody, Paul Aisen, Rema Raman, David S. Miller, Ann Marie Hake, Jeffrey L. Cummings	23
14	Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia 2015 ·Psychosomatics ·Elisabeth K. Degenhardt, Michael M. Witte, Michael Case, Peng Yu, David Henley, Helen Hochstetler, Deborah N. D’Souza, Paula T. Trzepacz	43
15	Florbetapir F18 PET Amyloid Neuroimaging and Baseline Characteristics in Patients with Alzheimer’s Dementia (P3.209) 2014 ·Neurology ·Elisabeth K. Degenhardt, Michael M. Witte, Michael Case, (unknown), David Henley, Helen Hochstetler, Deborah N. D’Souza, Paula T. Trzepacz	1
16	Establishing native plants in a weedy riparian environment 2011 ·New Zealand Journal of Marine and Freshwater Research ·Simeon J. Smaill, N. J. Ledgard, E.R. Langer, David Henley	9
17	An Integrated Analysis of Olanzapine/Fluoxetine Combination in Clinical Trials of Treatment-Resistant Depression 2009 ·The Journal of Clinical Psychiatry ·Madhukar H. Trivedi, Michael E. Thase, Olawale Osuntokun, David Henley, Michael Case, Susan B. Watson, (unknown), S. Corya	50
18	Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease 2009 ·Expert Opinion on Pharmacotherapy ·David Henley, Patrick C. May, Robert A. Dean, Eric Siemers	133
19	A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder 2007 ·The Journal of Clinical Psychiatry ·Michael E. Thase, S. Corya, Olawale Osuntokun, Michael Case, David Henley, T.M. Sanger, Susan B. Watson, Sanjay Dubé	171
20	Ecosystem carbon accretion 10 years after afforestation of depleted subhumid grassland planted with three densities of Pinus nigra 2007 ·Global Change Biology ·Murray R. Davis, (unknown), David Henley, Michael S. Watt	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact